|
|||||
|
|
| 吉非替尼治疗晚期非小细胞肺癌的疗效分析 | |
| 引用本文： | 林彬,张轶. 吉非替尼治疗晚期非小细胞肺癌的疗效分析[J]. 中国临床医学, 2010, 17(6): 807-808 |
| 作者姓名： | 林彬 张轶 |
| 作者单位： | 江苏省无锡卫生高等职业技术学校,江苏无锡214028 |
| 摘 要： | 目的：观察吉非替尼治疗晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）的临床疗效及不良反应。方法：回顾分析2008年5月—2010年5月期间口服吉非替尼250mg每日1次,并获得随访的43例晚期NSCLC患者的临床资料,评价其临床疗效及不良反应。结果：总有效率为23.25%,完全缓解（CR）2例（4.65%）,部分缓解（PR）8例（18.60%）,疾病稳定（SD）18例（41.86%）,疾病控制率为65.11%。出现的主要的不良反应为皮疹20例（46.51%）及腹泻、恶心呕吐等消化道反应16例（37.20%）,未出现Ⅲ~Ⅳ级严重不良反应。结论：吉非替尼治疗晚期NSCLC的临床疗效较好,并且不良反应小,患者耐受性良好。 |
| 关 键 词： | 吉非替尼 非小细胞肺癌 疗效 |
Clinical Effiacy and Safety of Gefitinib in Treating Advanced Non-small Cell Lung Cancer |
|
| LIN Bin,ZHANG Yi. Clinical Effiacy and Safety of Gefitinib in Treating Advanced Non-small Cell Lung Cancer[J]. Chinese Journal Of Clinical Medicine, 2010, 17(6): 807-808 | |
| Authors: | LIN Bin ZHANG Yi |
| Affiliation: | Wuxi Higher Health Vocational Thechonogy School,Wuxi 214028,China |
| Abstract: | Objective：To study the efficacy and safety of Gefitinib in the treatment of patients with advanced non-small cell lung cancer（NSCLC）.Methods：During May 2008 to May 2010,43 patients with advanced NSCLC were administrated Gefitinib 250 mg orally every day.The curative effect and adverse reaction were analyzed retrospectively.Results：The total effective rate was 23.25%,complete response（CR） 2 cases（4.65%）,partial response（PR） 8 cases（18.60%）,stable disease（SD） 19 cases（41.86%）,the disease control rate was 65.11%.The main adverse reaction was exanthem and gastrointestinal adverse reaction such as diarrhea,nausea and vomiting.Conclusions：Gefitinib has a dood curative effect and is tolerable to treat advanced NSCLC,and the adverse effect is gently. |
| Keywords: | Gefitinib Non-small cell lung cancer Efficacy Safety |
| 本文献已被 维普 万方数据 等数据库收录！ | |